DISA Uranium has agreed to acquire a portfolio of uranium projects in Colorado from Premier American Uranium, expanding its footprint in the western US uranium sector. The deal includes a $5 million strategic equity investment in Premier American Uranium, giving DISA a board seat and aligning the companies for future collaboration. This acquisition complements DISA's existing assets in Utah and supports its strategy to consolidate domestic uranium resources using its proprietary remediation technology. The transaction aims to enhance the US uranium supply chain by increasing feedstock sources and developing new recovery and processing capacity.
DISA Uranium's recent strategic transaction with Premier American Uranium provides context for the Basic Materials sector. For readers following this sector, here is Pluang's market snapshot as of Sep 15, 2026 16:51 WIB: out of 32 priced US Basic Materials stocks tradable on Pluang, 10 rose and 20 fell. Notable movers include NEM (Newmont Corporation) at USD 121.83 with a -1.01% change, KGC (Kinross Gold Corporation) at USD 27.90 with a -0.99% change, and ALB (Albemarle Corp.) at USD 114.00 with a -0.90% change.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
